Carisma Therapeutics (CARM) Competitors $0.24 +0.01 (+2.88%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.24 +0.00 (+0.42%) As of 08/22/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CARM vs. EVGN, IPSC, STTK, ALGS, TPST, JSPR, ATHE, KLRS, NBRV, and PYRGFShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Evogene (EVGN), Century Therapeutics (IPSC), Shattuck Labs (STTK), Aligos Therapeutics (ALGS), Tempest Therapeutics (TPST), Jasper Therapeutics (JSPR), Alterity Therapeutics (ATHE), Kalaris Therapeutics (KLRS), Nabriva Therapeutics (NBRV), and PyroGenesis Canada (PYRGF). Carisma Therapeutics vs. Its Competitors Evogene Century Therapeutics Shattuck Labs Aligos Therapeutics Tempest Therapeutics Jasper Therapeutics Alterity Therapeutics Kalaris Therapeutics Nabriva Therapeutics PyroGenesis Canada Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk. Is CARM or EVGN more profitable? Evogene has a net margin of -211.61% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -192.17% Evogene -211.61%-109.96%-38.47% Which has more volatility and risk, CARM or EVGN? Carisma Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Do analysts prefer CARM or EVGN? Carisma Therapeutics currently has a consensus price target of $1.93, suggesting a potential upside of 715.68%. Evogene has a consensus price target of $3.50, suggesting a potential upside of 168.20%. Given Carisma Therapeutics' higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71Evogene 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media favor CARM or EVGN? In the previous week, Evogene had 6 more articles in the media than Carisma Therapeutics. MarketBeat recorded 8 mentions for Evogene and 2 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.59 beat Carisma Therapeutics' score of 0.40 indicating that Evogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evogene 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of CARM or EVGN? 44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation and earnings, CARM or EVGN? Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.50-$60.48M-$1.56-0.15Evogene$8.51M0.82-$16.49M-$2.25-0.58 SummaryCarisma Therapeutics and Evogene tied by winning 8 of the 16 factors compared between the two stocks. Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.86M$2.54B$5.82B$9.76BDividend YieldN/A1.67%4.40%4.04%P/E Ratio-0.1522.7131.3826.05Price / Sales0.50752.44472.41122.40Price / CashN/A26.0925.7828.78Price / Book-0.355.599.526.07Net Income-$60.48M$31.83M$3.26B$265.39M7 Day Performance-19.18%1.89%2.14%2.00%1 Month Performance-40.16%1.62%3.22%0.46%1 Year Performance-79.12%9.25%30.19%18.88% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics2.9809 of 5 stars$0.24+2.9%$1.93+715.7%-79.1%$9.86M$19.63M-0.1520News CoverageShort Interest ↓EVGNEvogene2.7016 of 5 stars$1.33-1.8%$3.50+164.0%-66.4%$7.24M$8.51M-0.49140IPSCCentury Therapeutics3.0118 of 5 stars$0.57+2.2%$3.75+552.9%-69.8%$48.40M$6.59M-1.98170News CoverageAnalyst RevisionSTTKShattuck Labs3.5087 of 5 stars$1.02+2.0%$7.00+586.3%-72.6%$47.90M$5.72M-0.84100News CoverageALGSAligos Therapeutics4.4112 of 5 stars$8.77+13.9%$50.00+470.1%-26.2%$47.37M$3.94M-0.4490Positive NewsAnalyst RevisionTPSTTempest Therapeutics1.1713 of 5 stars$10.16-3.5%$30.00+195.3%-45.7%$46.76MN/A-0.7020JSPRJasper Therapeutics3.2079 of 5 stars$2.93-5.8%$28.75+881.2%-84.8%$46.72MN/A-0.4920ATHEAlterity Therapeutics2.1933 of 5 stars$5.22-0.6%$12.00+129.9%+286.2%$46.55MN/A0.0010KLRSKalaris Therapeutics1.2592 of 5 stars$2.50+1.6%$3.00+20.0%N/A$46.01MN/A0.00110Gap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070PYRGFPyroGenesis CanadaN/A$0.24-6.1%N/A-62.9%$45.44M$9.14M-4.0490Gap UpHigh Trading Volume Related Companies and Tools Related Companies Evogene Alternatives Century Therapeutics Alternatives Shattuck Labs Alternatives Aligos Therapeutics Alternatives Tempest Therapeutics Alternatives Jasper Therapeutics Alternatives Alterity Therapeutics Alternatives Kalaris Therapeutics Alternatives Nabriva Therapeutics Alternatives PyroGenesis Canada Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARM) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access